Lord Mendelsohn: To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 12 April 2022 (HL7711), given the data referred to, what update they can provide on (1) evidence of immune response in immunocompromised and immunosuppressed patients, and (2) the size of the cohort of people who do not produce antibodies from vaccines.
Lord Mendelsohn: To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 12 April 2022 (HL7711), what the findings of the OCTAVE-DUO work were on providing evidence of immune response following subsequent vaccine doses for the immunocompromised.
Lord Mendelsohn: To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 7 June 2022 (HL500), which advisory body reviewed the National Institute for Health and Care Research rapid study on those who remain vulnerable to poor outcomes from COVID-19 despite vaccination; and what conclusions it drew from the review.
Lord Kamall: The noble Lord opposite talked about the website for resilience. For the benefit of noble Lords who are not yet aware of this website, can my noble friend the Minister share the URL for that website so that we can evangelise about it on her behalf?
Lord Kamall: My Lords, following the question from the noble Lord opposite, would counselling also be offered?
Lord Hunt of Kings Heath: To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 2 August 2022 (HL1602), what is the current list of 'purposes' available today in NHS England’s Palantir platform; and how many users are currently able to access each purpose listed.
Lord Kamall: To ask His Majesty's Government, further to the Written Answer by Lord Bellamy on 2 May (HL6631), how many times magistrate courts have awarded a sentence of more than the Sentencing Council's maximum sentence for any offence, where the legal maximum is longer than the Sentencing Council's guidelines, in the past five years.
Lord Kamall: To ask His Majesty's Government, further to the remarks of Lord Harlech on 21 September (HL Deb col 1533), whether any companies have asked them to maintain mandatory reporting on food waste, what were those companies, and whether any such companies have offered to pay the costs of that reporting rather than using public money.
Lord Kamall: To ask His Majesty's Government, further to the Written Answer by Lord Johnson of Lainston on 1 February (HL1695), what assessment they have made of the impact of not renewing the Recovery Loan Scheme on small businesses in deprived areas who have previously been turned down for loans by high street banks.
Jonathan Patrick Moynihan, OBE, having been created Baron Moynihan of Chelsea, of Chelsea in the Royal Borough of Kensington and Chelsea, was introduced and made the solemn affirmation, supported by Lord Moore of Etchingham and Lord Kamall, and signed an undertaking to abide by the Code of Conduct.
Lord Kamall: ...including Diabetes UK, are looking at the most effective way to tackle diabetes but also to understand the trade-offs that must be made and the balance of considerations. I will write to the noble Lord on the detail of his question.
Lord Kamall: I thank the noble Lord for giving me notice of his question just before we came in. I tried to get an answer as quickly as possible, and I apologise that that answer has not arrived. I want to make sure it is absolutely right and that I am certain that I do not mislead the House unintentionally.
Lord Mendelsohn: To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 7 June 2022 (HL500), what work was undertaken by NHS Digital in June 2022 (1) to improve the access to relevant data which identifies those who are immunocompromised, and (2) to build a technical platform to identify such patients for different interventions, such as treatments and vaccines.
Lord Alton of Liverpool: To ask Her Majesty's Government, further to the Written Answers by Lord Kamall on 2 November (HL3362) and 1 December (HL4059), what steps the Human Fertilisation and Embryology Authority have taken in response to the publication by Newcastle University Press Office on 15 December 2016 of the names and picture of a couple considering using the mitochondrial donation technique.
Lord Mendelsohn: To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 23 June 2022 (HL731), what specific data is collected on the number of treatments prescribed and administered by the COVID Medicines Delivery Units in England; where this information can be accessed; and which body is tasked with overseeing and acting on the results of this data.
Lord Alton of Liverpool: To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 16 November (HL3662), how performance of pronuclear transfer in mice might remain a reliable predictor of its efficacy in humans; and to what extent the physiopathological or genetic variation between human patients is greater than the physiological or genetic differences between humans and mice.
Lord Alton of Liverpool: To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 2 November (HL3362), what were the affected genes in the mitochondrial genome and the associated mutations in each of the 24 patients licensed as eligible for mitochondrial replacement treatment; and on what dates each corresponding application was approved by the Human Fertilisation and Embryology Authority.
Lord Mendelsohn: To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 21 June 2022 (HL728), what is the "recent evidence" that "antivirals and neutralising monoclonal antibodies significantly improve clinical outcomes in non-hospitalised patients with COVID-19 who are at high risk of progression to severe disease"; and whether they will make this evidence available, including any...
Lord Hunt of Kings Heath: To ask His Majesty's Government, further to the Written Answer by Lord Kamall on 2 August 2022 (HL1602), whether they will (1) publish, or (2) place in the Library of the House, a copy of the form(s) for NHS England staff to request access to data in Palantir Foundry software and any associated training materials about making such requests.
Lord Kamall: Moved by Lord Kamall 5: Clause 5, page 3, line 15, leave out “The reference in subsection (1)” and insert “In subsection (1)—(a) the reference”Member’s explanatory statementThis amendment is consequential on another amendment which provides that references in new section 13NA of the NHS Act 2006 to effects of a decision in relation to certain matters include its...